Z
Zafgen
A biopharmaceutical company that develops obesity therapeutics.
About Zafgen
Zafgen, now part of Larimar Therapeutics, is a biopharmaceutical company dedicated to developing innovative therapies for rare metabolic diseases. The company primarily targets conditions such as Prader-Willi syndrome and other genetic disorders that result in severe metabolic dysfunction. Operating in the highly specialized field of rare disease treatment, Zafgen serves a niche market of patients with limited therapeutic options. The business model revolves around the research, development, and commercialization of novel drug candidates. Revenue is generated through the successful development and subsequent licensing or sale of these therapies to larger pharmaceutical companies or directly to healthcare providers. Zafgen's strategic focus on rare diseases allows it to benefit from orphan drug designations, which can provide market exclusivity and financial incentives.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Cambridge, United States
- Employees
- 81
- Open positions
- 45
- Dealroom signal
- 62.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Weight Management, Nutrition, Spinout, Metabolism, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Jun 2014 | $0 | — | Undisclosed | — |
| DEBTDebt | Apr 2014 | $20M | — | Midcap Financial | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Zafgen is 250 monthly website visits, down 80.8% over the last three months. Zafgen's team grew 1.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Atlas Venture
GreatPoint Ventures
Third Rock Ventures
Series B and later5 investors entered at this stage
Alta Partners
Venrock
Brookside Capital
RA Capital Management
Midcap Financial
Other known investors2 additional known investors
Children’s Hospital Boston
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zafgen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zafgen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.